Methodology and Evidence Review 1752 Organization of Committee and Relationships With Industry 1752 1.3. Review and Approval 1752 2. Diagnosis of SIHD 1753 Invasive Testing for Diagnosis of Coronary Artery Disease in Patients s With Suspected SIHD: Recommendations (New Section) 1753 4. Treatment 1755 4.4. Guideline-Directed Medical Therapy 1755 Additional Medical Therapy to Prevent MI and Death: Recommendation 1755 Additional Therapy to Reduce Risk of MI and Death 1755 4.4.2.5.4. Chelation Therapy 1755 Alternative Therapies for Relief of Symptoms in Patients With Refractory Angina: Recommendation 1755 4.4.4.1. Enhanced External Counterpulsation 1755 5. CAD Revascularization 1756 Revascularization to Improve Survival: Recommendations 1756 5.6. CABG Versus PCI 1756 5.6.2. CABG Versus Drug-Eluting Stents 1756 Studies Comparing PCI Versus CABG for Left Main CAD 1757 5.12. Special Considerations 1758 5.12.3. Diabetes Mellitus 1758 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 1762 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 1764 Preamble Keeping pace with emerging evidence is an ongoing chal- lenge to timely development of clinical practice guidelines. In an effort to respond promptly to new evidence, the American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines (Task Force) has cre- ated a focused update process to revise the existing guideline recommendations that are affected by evolving data or opinion. New evidence is reviewed in an ongoing manner to respond quickly to important scientific and treatment trends that could have a major impact on patient outcomes and quality of care. Evidence is reviewed at least twice a year, and updates are initi- ated on an as-needed basis and completed as quickly as possible while maintaining the rigorous methodology that the ACC and AHA have developed during their partnership of >20 years. 